Abstract
Cancer-associated muscle weakness is a poorly understood phenomenon, and there is no effective treatment. Here we find that seven different mouse models of human osteolytic bone metastases—representing breast, lung and prostate cancers, as well as multiple myeloma—exhibited impaired muscle function, implicating a role for the tumor-bone microenvironment in cancer-associated muscle weakness. We found that transforming growth factor (TGF)-β, released from the bone surface as a result of metastasis-induced bone destruction, upregulated NADPH oxidase 4 (Nox4), resulting in elevated oxidization of skeletal muscle proteins, including the ryanodine receptor and calcium (Ca2+) release channel (RyR1). The oxidized RyR1 channels leaked Ca2+, resulting in lower intracellular signaling, which is required for proper muscle contraction. We found that inhibiting RyR1 leakage, TGF-β signaling, TGF-β release from bone or Nox4 activity improved muscle function in mice with MDA-MB-231 bone metastases. Humans with breast- or lung cancer–associated bone metastases also had oxidized skeletal muscle RyR1 that is not seen in normal muscle. Similarly, skeletal muscle weakness, increased Nox4 binding to RyR1 and oxidation of RyR1 were present in a mouse model of Camurati-Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-β activity. Thus, pathological TGF-β release from bone contributes to muscle weakness by decreasing Ca2+-induced muscle force production.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fearon, K.C., Glass, D.J. & Guttridge, D.C. Cancer cachexia: mediators, signaling and metabolic pathways. Cell Metab. 16, 153–166 (2012).
Gentry, B.A., Ferreira, J.A., Phillips, C.L. & Brown, M. Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve 43, 49–57 (2011).
Mendias, C.L., Marcin, J.E., Calerdon, D.R. & Faulkner, J.A. Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J. Appl. Physiol. 101, 898–905 (2006).
Weilbaecher, K.N., Guise, T.A. & McCauley, L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411–425 (2011).
Coleman, R.E. et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat. Rev. 36, 615–620 (2010).
Kang, Y. et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA 102, 13909–13914 (2005).
Korpal, M. et al. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960–966 (2009).
Tang, Y. et al. TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15, 757–765 (2009).
Zalk, R., Lehnart, S.E. & Marks, A.R. Modulation of the ryanodine receptor and intracellular calcium. Annu. Rev. Biochem. 76, 367–385 (2007).
Andersson, D.C. et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14, 196–207 (2011).
Guise, T.A. et al. Evidence for a causal role of parathyroid hormone–related protein in the pathogenesis of human breast cancer–mediated osteolysis. J. Clin. Invest. 98, 1544–1549 (1996).
Vera-Ramirez, L. et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit. Rev. Oncol. Hematol. 80, 347–368 (2011).
Bellinger, A.M. et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15, 325–330 (2009).
Lu, X. & Kang, Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl. Acad. Sci. USA 106, 9385–9390 (2009).
Guise, T.A., Yoneda, T., Yates, A.J. & Mundy, G.R. The combined effect of tumor-produced parathyroid hormone–related protein and transforming growth factor-α enhance hypercalcemia in vivo and bone resorption in vitro. J. Clin. Endocrinol. Metab. 77, 40–45 (1993).
Hjorth-Hansen, H. et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J. Bone Miner. Res. 14, 256–263 (1999).
Bellinger, A.M. et al. Remodeling of ryanodine receptor complex causes 'leaky' channels: a molecular mechanism for decreased exercise capacity. Proc. Natl. Acad. Sci. USA 105, 2198–2202 (2008).
Andersson, D.C. & Marks, A.R. Fixing ryanodine receptor Ca leak: a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov. Today Dis. Mech. 7, e151–e157 (2010).
Dallas, S.L., Rosser, J.L., Mundy, G.R. & Bonewald, L.F. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix. J. Biol. Chem. 277, 21352–21360 (2002).
Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003).
Yin, J.J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197–206 (1999).
Shi, Y. & Massagué, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685–700 (2003).
Dasch, J.R., Pace, D.R., Waegell, W., Inenaga, D. & Ellingsworth, L. Monoclonal antibodies recognizing transforming growth factor–β. Bioactivity neutralization and transforming growth factor β2 affinity purification. J. Immunol. 142, 1536–1541 (1989).
Biswas, S. et al. Anti–transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS ONE 6, e27090 (2011).
Sun, Q.A. et al. Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc. Natl. Acad. Sci. USA 108, 16098–16103 (2011).
Carmona-Cuenca, I. et al. Upregulation of the NADPH oxidase NOX4 by TGF-β in hepatocytes is required for its pro-apoptotic activity. J. Hepatol. 49, 965–976 (2008).
Hubackova, S., Krejcikova, K., Bartek, J. & Hodny, Z. IL1- and TGF-β–Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced and drug-induced paracrine 'bystander senescence'. Aging (Albany NY) 4, 932–951 (2012).
Michaeloudes, C., Sukkar, M.B., Khorasani, N.M., Bhavsar, P.K. & Chung, K.F. TGF-β regulates Nox4, MnSOD and catalase expression and IL-6 release in airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 300, L295–L304 (2011).
Yan, F. et al. Nox4 and redox signaling mediate TGF-β–induced endothelial cell apoptosis and phenotypic switch. Cell Death Dis. 5, e1010 (2014).
Jiang, J.X. et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic. Biol. Med. 53, 289–296 (2012).
Janssens, K. et al. Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati-Engelmann disease. Nat. Genet. 26, 273–275 (2000).
Janssens, K., ten Dijke, P., Ralston, S.H., Bergmann, C. & Van Hul, W. Transforming growth factor-β1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J. Biol. Chem. 278, 7718–7724 (2003).
Mendias, C.L. et al. Transforming growth factor-β induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45, 55–59 (2012).
Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531–543 (2010).
McPherron, A.C., Lawler, A.M. & Lee, S.J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387, 83–90 (1997).
Bogdanovich, S. et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418–421 (2002).
Wehrens, X.H. et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292–296 (2004).
Dunn, L.K. et al. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 4, e6896 (2009).
Soule, H.D., Vazguez, J., Long, A., Albert, S. & Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51, 1409–1416 (1973).
Yin, J.J. et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA 100, 10954–10959 (2003).
Hu, Z. et al. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum. Gene Ther. 23, 871–882 (2012).
Johnson, R.W. et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin. Exp. Metastasis 31, 945–959 (2014).
Jackson, N. et al. Two new IgA1-κ plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin. Exp. Immunol. 75, 93–99 (1989).
Bonetto, A., Andersson, D.C. & Waning, D.L. Assessment of muscle mass and strength in mice. Bonekey Rep. 4, 732 (2015).
Yamada, T. et al. Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum. 60, 3280–3289 (2009).
Aydin, J. et al. Increased mitochondrial Ca2+ and decreased sarcoplasmic reticulum Ca2+ in mitochondrial myopathy. Hum. Mol. Genet. 18, 278–288 (2009).
Lai, X. et al. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin. Appl. 2, 1140–1152 (2008).
Keller, A., Nesvizhskii, A.I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392 (2002).
Nesvizhskii, A.I., Keller, A., Kolker, E. & Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646–4658 (2003).
Lai, X., Wang, L., Tang, H. & Witzmann, F.A. A novel alignment method and multiple filters for exclusion of unqualified peptides to enhance label-free quantification using peptide intensity in LC-MS/MS. J. Proteome Res. 10, 4799–4812 (2011).
Mohammad, K.S. et al. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4, e5275 (2009).
Kimura, Y., Kurzydlowski, K., Tada, M. & MacLennan, D.H. Phospholamban regulates the Ca2+-ATPase through intramembrane interactions. J. Biol. Chem. 271, 21726–21731 (1996).
Cheng, H. et al. Amplitude distribution of calcium sparks in confocal images: theory and studies with an automatic detection method. Biophys. J. 76, 606–617 (1999).
de Winter, J.C.F. Using the Student's t-test with extremely small sample sizes. Pract. Assess., Res. Eval. 18, 1–12 (2013).
Acknowledgements
This work was supported by the US National Institutes of Health (NIH) (grant U01CA143057 (T.A.G.) from the National Cancer Institute (NCI) Tumor Microenvironment Network, NCI-R01CA69158 (T.A.G.), NCI-R21CA179017 (G.D.R.), NHLBI-R01HL061503 (A.R.M.), NHLBI-R01HL102040 (A.R.M.), NIAMS-R01AR060037 (A.R.M.), NIH T32 HL120826 (A.R.M.), NINDS-R25NS076445 (A.R.M.), NIH-NINDS R25NS076445 (A.H.), NIH-NIAMS R01AR063943 (X.C.), and NIH-NHLBI T35 HL110854-01 (S.C. and P.K.)), the Susan G. Komen Foundation (grant SAC110013; T.A.G.), the Indiana Economic Development Grant (T.A.G.), the Jerry and Peggy Throgmartin Endowment of the Indiana University Simon Cancer Center (T.A.G.), the Indiana University Simon Cancer Center Breast Cancer Program (T.A.G.), the American Cancer Society and Indiana University Simon Cancer Center (grant IRG-84-002-28; D.L.W.), the Indiana University Health Strategic Research Initiative in Oncology (D.L.W.), the VA Merit Review Award (G.D.R.), the Fondation Leducq (A.R.M.), the Ellison Foundation (A.R.M.), the Swedish Heart Lung Foundation and Stockholm County Council (D.C.A.) and a generous donation from the Withycombe family (T.A.G.). Camurati-Engelmann disease (CED) mice were previously described and provided by X. Cao (Johns Hopkins, Baltimore, MD).
Author information
Authors and Affiliations
Contributions
All contributing authors have agreed to submission of this manuscript for publication. T.A.G. and A.R.M. conceived of the study. D.L.W., K.S.M., A.R.M. and T.A.G. designed and performed experiments, analyzed data and interpreted results. S.R., W.X., D.C.A., S.J., M.N., A.C., L.E.W., A.W., A.H., A.U., T.T., S.C., F.A.W. and P.K. performed experiments. M.S.B. analyzed data. G.D.R. and F.A.W. designed experiments and interpreted results. G.Z., X.W. and X.C. provided the CED mice and reviewed the results. D.L.W., K.S.M., A.R.M. and T.A.G. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
A.R.M. is a member of the board and consults for ARMGO Pharma Inc., a startup company developing RyR-targeted therapeutics; T.A.G. was a consultant and advisory board member for Novartis.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8 and Supplementary Tables 1–3 (PDF 26024 kb)
Rights and permissions
About this article
Cite this article
Waning, D., Mohammad, K., Reiken, S. et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med 21, 1262–1271 (2015). https://doi.org/10.1038/nm.3961
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3961
This article is cited by
-
Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer
Scientific Reports (2024)
-
Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilans
EMBO Molecular Medicine (2024)
-
The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health
Current Osteoporosis Reports (2024)
-
Decreased expression of H19/miR-675 ameliorates muscle atrophy by regulating the IGF1R/Akt/FoxO signaling pathway
Molecular Medicine (2023)
-
Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer
BMC Medicine (2023)